DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
ENMD-1198 is an investigational drug.
There have been 8 clinical trials for ENMD-1198. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Sarcoma. The leading clinical trial sponsors are CASI Pharmaceuticals, Inc., University Health Network, Toronto, and University of Colorado, Denver.
There are two US patents protecting this investigational drug and six international patents.
Recent Clinical Trials for ENMD-1198
|A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma||CASI Pharmaceuticals, Inc.||Phase 2|
|A Study of ENMD-2076 in Ovarian Clear Cell Cancers||University Health Network, Toronto||Phase 2|
|Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma||University Health Network, Toronto||Phase 2|
Top disease conditions for ENMD-1198
Top clinical trial sponsors for ENMD-1198
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ENMD-1198||Start Trial||Antiangiogenic agents||EntreMed, Inc. (Rockville, MD)||Start Trial|
|ENMD-1198||Start Trial||Methods of treating disease states using antiangiogenic agents||EntreMed, Inc. (Rockville, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ENMD-1198||European Patent Office||1756139||2024-03-12||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|